- You can view the full Akorn Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
M&A, French election relief and renewed talk of reforms to taxes and trade all helped to push European stocks higher Tuesday
Here are Tuesday's top research calls, including downgrades for Amazon and C.R. Bard, and new coverage of CyrusOne and Dow Chemical.